DarioHealth

Company Overview

Snapshot

Founded in September 2011 by Dov Oppenheim, DarioHealth operates with 201–500 employees. The company has raised over $244.61 million across 17 funding rounds. In February 2024, DarioHealth acquired Twill, a digital health firm, for $10 million in cash and approximately 10 million shares of common stock, aiming to enhance its digital health platform for chronic conditions.

Business overview

DarioHealth is a global digital therapeutics company that aims to transform how individuals manage chronic conditions, offering highly-rated solutions for diabetes and hypertension. Its AI-powered digital therapeutic solutions provide adaptive, personalized experiences to drive behavior change through evidence-based interventions, high-quality software, coaching, and clinically proven digital tools. Operating at the intersection of life sciences, behavioral science, and software technology, DarioHealth is expanding into new chronic conditions and geographic markets with a performance-based approach to improve user health.

Strategic signal

In June 2026, DarioHealth presented four studies at the American Diabetes Association Scientific Sessions, highlighting the commercial and clinical value of its digital health platform. This signals strong scientific validation and market readiness for its solutions, reinforcing investor confidence in the company's ability to deliver measurable health outcomes and expand its commercial footprint.

Company Intelligence Q&A

What was the outcome of DarioHealth's Q1 2026 financial results?

DarioHealth reported its Q1 2026 financial and operating results in May 2026, with revenues increasing to $5.6 million, marking the second consecutive quarter of sequential growth. Operating expenses decreased by 21%.

What strategic expansion did DarioHealth announce in May 2026?

In May 2026, DarioHealth announced it more than doubled its addressable market in Solera Health's network through an expanded hypertension program, now reaching over 500,000 eligible lives.

What significant scientific milestone did DarioHealth achieve in January 2026?

In January 2026, DarioHealth surpassed 100 scientific studies, cementing its leadership as one of the most evidence-based platforms in digital health. This milestone reinforces its position as a trusted partner for organizations seeking to reduce costs and improve health outcomes.

What was the strategic focus of DarioHealth's new GLP-1 digital health solution in March 2026?

In March 2026, DarioHealth highlighted its unique position to amplify the impact of oral GLP-1 therapies through precision behavioral support, with 79% of members already using Dario's weight management. This solution addresses increasing demand from employers and health plans by integrating structured behavioral reinforcement to optimize GLP-1 outcomes.

What management change occurred at DarioHealth in April 2025?

In April 2025, DarioHealth announced a CFO transition, with Zvi Ben-David retiring and Chen Franco-Yehuda appointed as the new CFO, Treasurer, and Secretary, effective May 15, 2025. Franco-Yehuda's expertise is expected to drive DarioHealth's financial strategy and growth initiatives.